Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN)
ConclusionA frailty assessment with appropriate dose modification for induction therapy should be mandatory for all elderly non-transplant-eligible myeloma patients.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Germany Health | Myeloma | Prednisolone | Revlimid | Study | Toxicology | Transplants | Velcade